Literature DB >> 21873557

Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance.

Wen Yang1, Marina Yamada, Yoshiaki Tamura, Kyungho Chang, Ji Mao, Lin Zou, Yan Feng, Kotaro Kida, Marielle Scherrer-Crosbie, Wei Chao, Fumito Ichinose, Yong-Ming Yu, Alan J Fischman, Ronald G Tompkins, Shanglong Yao, Masao Kaneki.   

Abstract

Treatment with statins, inhibitors of HMG-CoA reductase, extends the survival of septic mice. However, the molecular mechanisms underlying the cholesterol-lowering, independent beneficial effects of statins in sepsis are poorly understood. The inhibition of protein isoprenylation, namely farnesylation and geranylgeranylation, has been proposed as a mediator of the pleiotropic protective effects of statins, although direct evidence is lacking. Major features of sepsis-induced immune suppression include T-cell dysfunction, which is characterized by apoptosis of splenic T cells, increased CD4(+)Foxp3(+) regulatory T cells (Tregs), and suppression of type 1 helper T-cell response [e.g., interferon-γ (IFN-γ) secretion] in mice. Here, we show that the induction of sepsis by cecal ligation and puncture (CLP) resulted in increases in farnesyltransferase activity and farnesylated proteins in the spleen relative to sham operation. Treatment with farnesyltransferase inhibitor N-[4-[2(R)-amino-3-mercaptopropyl]amino-2-phenylbenzoyl]methionine methyl ester trifluoroacetate salt (FTI-277) (25 mg/kg b.wt. i.p.) at 2 h after CLP blocked the increase in farnesylated proteins and improved survival and bacterial clearance of septic mice. FTI-277 reverted to or mitigated sepsis-induced apoptosis in spleen and thymus, increased splenic CD4(+)Foxp3(+) Tregs, and suppressed IFN-γ secretion and proliferation of splenocytes in response to anti-CD3+CD28 antibodies in mice. Moreover, FTI-277 promoted macrophage phagocytotic activity in septic mice. These results indicate that elevation in protein farnesylation plays a role in derangements in immune function and mortality of septic mice. These findings suggest that prevention of immune dysfunction might contribute to FTI-277-induced improvement in survival of septic mice. These data highlight protein farnesyltransferase as a novel potential molecular target to reduce the mortality of patients with sepsis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21873557      PMCID: PMC3226365          DOI: 10.1124/jpet.111.183558

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  Alpha-subunit of farnesyltransferase is phosphorylated in vivo: effect of protein phosphatase-1 on enzymatic activity.

Authors:  A Kumar; M H Beresini; P Dhawan; K D Mehta
Journal:  Biochem Biophys Res Commun       Date:  1996-05-15       Impact factor: 3.575

2.  Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells.

Authors:  Hiroki Sugita; Masaki Fujimoto; Takashi Yasukawa; Nobuyuki Shimizu; Michiko Sugita; Shingo Yasuhara; J A Jeevendra Martyn; Masao Kaneki
Journal:  J Biol Chem       Date:  2005-02-01       Impact factor: 5.157

3.  Insulin stimulates the phosphorylation and activity of farnesyltransferase via the Ras-mitogen-activated protein kinase pathway.

Authors:  M Goalstone; K Carel; J W Leitner; B Draznin
Journal:  Endocrinology       Date:  1997-12       Impact factor: 4.736

4.  Murine guanylate-binding protein: incomplete geranylgeranyl isoprenoid modification of an interferon-gamma-inducible guanosine triphosphate-binding protein.

Authors:  J T Stickney; J E Buss
Journal:  Mol Biol Cell       Date:  2000-07       Impact factor: 4.138

5.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

6.  Lovastatin protects against experimental plague in mice.

Authors:  Saravanan Ayyadurai; Hubert Lepidi; Claude Nappez; Didier Raoult; Michel Drancourt
Journal:  PLoS One       Date:  2010-06-02       Impact factor: 3.240

7.  Prior statin therapy is associated with a decreased rate of severe sepsis.

Authors:  Yaniv Almog; Alexander Shefer; Victor Novack; Nimrod Maimon; Leonid Barski; Miruna Eizinger; Michael Friger; Lior Zeller; Abraham Danon
Journal:  Circulation       Date:  2004-08-02       Impact factor: 29.690

8.  Akt decreases lymphocyte apoptosis and improves survival in sepsis.

Authors:  Ursula Bommhardt; Katherine C Chang; Paul E Swanson; Tracey H Wagner; Kevin W Tinsley; Irene E Karl; Richard S Hotchkiss
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

9.  HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis.

Authors:  Marc W Merx; Elisa A Liehn; Uwe Janssens; Rudolf Lütticken; Jürgen Schrader; Peter Hanrath; Christian Weber
Journal:  Circulation       Date:  2004-05-03       Impact factor: 29.690

10.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1.

Authors:  Huan Yang; Mahendar Ochani; Jianhua Li; Xiaoling Qiang; Mahira Tanovic; Helena E Harris; Srinivas M Susarla; Luis Ulloa; Hong Wang; Robert DiRaimo; Christopher J Czura; Haichao Wang; Jesse Roth; H Shaw Warren; Mitchell P Fink; Matthew J Fenton; Ulf Andersson; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

View more
  13 in total

Review 1.  Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions.

Authors:  Elaina A Zverina; Corissa L Lamphear; Elia N Wright; Carol A Fierke
Journal:  Curr Opin Chem Biol       Date:  2012-11-08       Impact factor: 8.822

2.  Streptococcal m1 protein triggers farnesyltransferase-dependent formation of CXC chemokines in alveolar macrophages and neutrophil infiltration of the lungs.

Authors:  Songen Zhang; Milladur Rahman; Su Zhang; Bengt Jeppsson; Heiko Herwald; Henrik Thorlacius
Journal:  Infect Immun       Date:  2012-09-04       Impact factor: 3.441

3.  Farnesyltransferase inhibitor, tipifarnib, prevents galactosamine/lipopolysaccharide-induced acute liver failure.

Authors:  Masao Kaneki; Fumito Ichinose; Kazuhiro Shirozu; Shuichi Hirai; Tomokazu Tanaka; Shinsuke Hisaka
Journal:  Shock       Date:  2014-12       Impact factor: 3.454

4.  Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.

Authors:  W Li; J Tu; X Liu; W Yang
Journal:  Clin Exp Immunol       Date:  2017-07-14       Impact factor: 4.330

Review 5.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

6.  Rho kinase regulates induction of T-cell immune dysfunction in abdominal sepsis.

Authors:  Z Hasan; K Palani; S Zhang; M Lepsenyi; R Hwaiz; M Rahman; I Syk; B Jeppsson; Henrik Thorlacius
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

Review 7.  Metabolic Inflammatory Complex in Sepsis: Septic Cachexia as a Novel Potential Therapeutic Target.

Authors:  Masao Kaneki
Journal:  Shock       Date:  2017-12       Impact factor: 3.454

8.  Myostatin deficiency not only prevents muscle wasting but also improves survival in septic mice.

Authors:  Masayuki Kobayashi; Shingo Kasamatsu; Shohei Shinozaki; Shingo Yasuhara; Masao Kaneki
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-12-07       Impact factor: 4.310

9.  Role of protein farnesylation in burn-induced metabolic derangements and insulin resistance in mouse skeletal muscle.

Authors:  Harumasa Nakazawa; Marina Yamada; Tomokazu Tanaka; Joshua Kramer; Yong-Ming Yu; Alan J Fischman; J A Jeevendra Martyn; Ronald G Tompkins; Masao Kaneki
Journal:  PLoS One       Date:  2015-01-16       Impact factor: 3.240

Review 10.  Statins as modulators of regulatory T-cell biology.

Authors:  David A Forero-Peña; Fredy R S Gutierrez
Journal:  Mediators Inflamm       Date:  2013-10-03       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.